Prognostic significance of TEL/AML1 fusion transcript in childhood B- precursor acute lymphoblastic leukemia

Yoshiyuki Takahashi, Keizo Horibe, Hitoshi Kiyoi, Yoshiko Miyashita, Minoru Fukuda, Hiroshi Mori, Chika Nozaki, Shinji Hasegawa, Takashi Kawabe, Koji Kato, Seiji Kojima, Takaharu Matuyama, Tomoki Naoe

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Purpose: A retrospective study was conducted to investigate the prognostic significance of TEL/AML1 fusion resulting from a cryptic t(12;21) in Japanese patients with childhood B-precursor acute lymphoblastic leukemia (ALL). Materials and Methods: Leukemic samples from 144 children with newly diagnosed ALL (104 with CD10-positive B-precursor ALL, 11 with CD10-negative B-precursor ALL, 5 with BALL, and 24 with T-ALL) were analyzed by reverse- transcription polymerase chain reaction. Results: The frequency of patients with TEL/AML1 was 16% (23 of 144) and all patients with TEL/AML1 also had CD10-positive B-precursor ALL. TEL/AML1 was not found in any samples from the patients with T-ALL, B-ALL, or CD10-negative B-precursor ALL. Among patients with CD10-positive B-precursor ALL, age, initial white blood cell count, and immunophenotype did not differ with TEL/AML1 positivity, although the patients were predominantly male (p < 0.01). Clinical outcomes of 94 patients treated with recent protocols were analyzed. Five of the 21 (23.8%) patients with TEL/AML1 relapsed and 4 of these relapsed > 24 months after diagnosis. Although the overall 5-year survival rate was better among patients with TEL/AML1 fusion transcript than among those without it (87.3 ± 8.7% versus 75.9 ± 5.8%, respectively), the 5-year disease-free survival (DFS) rates of patients with TEL/AML1 fusion transcript and those without it were similar (64.0 ± 13.5% versus 69.1 ± 6.3%, respectively). However, for 57 patients treated with the latest intensive protocol, the 4-year DFS rate was much higher for the patients with TEL/AML1 fusion transcript than for those without it (100.0% v.s. 69.6 ± 8.4%, respectively, p = 0.1472). Conclusions: This study confirmed that TEL/AML1 gene fusion is the most common genetic event in pediatric ALL in Japan and is restricted to CD10-positive B- precursor ALL. Moreover, it was associated with an improved survival rate among patients treated with intensive therapy. Therefore, these data suggest that the patients with TEL/AML1 may not necessarily be candidates for less aggressive treatment.

Original languageEnglish
Pages (from-to)190-195
Number of pages6
JournalJournal of Pediatric Hematology/Oncology
Volume20
Issue number3
DOIs
Publication statusPublished - May 1 1998

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Survival Rate
Disease-Free Survival
Gene Fusion
Leukocyte Count
Reverse Transcription
Japan
Retrospective Studies
Pediatrics
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Prognostic significance of TEL/AML1 fusion transcript in childhood B- precursor acute lymphoblastic leukemia. / Takahashi, Yoshiyuki; Horibe, Keizo; Kiyoi, Hitoshi; Miyashita, Yoshiko; Fukuda, Minoru; Mori, Hiroshi; Nozaki, Chika; Hasegawa, Shinji; Kawabe, Takashi; Kato, Koji; Kojima, Seiji; Matuyama, Takaharu; Naoe, Tomoki.

In: Journal of Pediatric Hematology/Oncology, Vol. 20, No. 3, 01.05.1998, p. 190-195.

Research output: Contribution to journalArticle

Takahashi, Y, Horibe, K, Kiyoi, H, Miyashita, Y, Fukuda, M, Mori, H, Nozaki, C, Hasegawa, S, Kawabe, T, Kato, K, Kojima, S, Matuyama, T & Naoe, T 1998, 'Prognostic significance of TEL/AML1 fusion transcript in childhood B- precursor acute lymphoblastic leukemia', Journal of Pediatric Hematology/Oncology, vol. 20, no. 3, pp. 190-195. https://doi.org/10.1097/00043426-199805000-00002
Takahashi, Yoshiyuki ; Horibe, Keizo ; Kiyoi, Hitoshi ; Miyashita, Yoshiko ; Fukuda, Minoru ; Mori, Hiroshi ; Nozaki, Chika ; Hasegawa, Shinji ; Kawabe, Takashi ; Kato, Koji ; Kojima, Seiji ; Matuyama, Takaharu ; Naoe, Tomoki. / Prognostic significance of TEL/AML1 fusion transcript in childhood B- precursor acute lymphoblastic leukemia. In: Journal of Pediatric Hematology/Oncology. 1998 ; Vol. 20, No. 3. pp. 190-195.
@article{18077964df01435d8639b33e05d4c33a,
title = "Prognostic significance of TEL/AML1 fusion transcript in childhood B- precursor acute lymphoblastic leukemia",
abstract = "Purpose: A retrospective study was conducted to investigate the prognostic significance of TEL/AML1 fusion resulting from a cryptic t(12;21) in Japanese patients with childhood B-precursor acute lymphoblastic leukemia (ALL). Materials and Methods: Leukemic samples from 144 children with newly diagnosed ALL (104 with CD10-positive B-precursor ALL, 11 with CD10-negative B-precursor ALL, 5 with BALL, and 24 with T-ALL) were analyzed by reverse- transcription polymerase chain reaction. Results: The frequency of patients with TEL/AML1 was 16{\%} (23 of 144) and all patients with TEL/AML1 also had CD10-positive B-precursor ALL. TEL/AML1 was not found in any samples from the patients with T-ALL, B-ALL, or CD10-negative B-precursor ALL. Among patients with CD10-positive B-precursor ALL, age, initial white blood cell count, and immunophenotype did not differ with TEL/AML1 positivity, although the patients were predominantly male (p < 0.01). Clinical outcomes of 94 patients treated with recent protocols were analyzed. Five of the 21 (23.8{\%}) patients with TEL/AML1 relapsed and 4 of these relapsed > 24 months after diagnosis. Although the overall 5-year survival rate was better among patients with TEL/AML1 fusion transcript than among those without it (87.3 ± 8.7{\%} versus 75.9 ± 5.8{\%}, respectively), the 5-year disease-free survival (DFS) rates of patients with TEL/AML1 fusion transcript and those without it were similar (64.0 ± 13.5{\%} versus 69.1 ± 6.3{\%}, respectively). However, for 57 patients treated with the latest intensive protocol, the 4-year DFS rate was much higher for the patients with TEL/AML1 fusion transcript than for those without it (100.0{\%} v.s. 69.6 ± 8.4{\%}, respectively, p = 0.1472). Conclusions: This study confirmed that TEL/AML1 gene fusion is the most common genetic event in pediatric ALL in Japan and is restricted to CD10-positive B- precursor ALL. Moreover, it was associated with an improved survival rate among patients treated with intensive therapy. Therefore, these data suggest that the patients with TEL/AML1 may not necessarily be candidates for less aggressive treatment.",
author = "Yoshiyuki Takahashi and Keizo Horibe and Hitoshi Kiyoi and Yoshiko Miyashita and Minoru Fukuda and Hiroshi Mori and Chika Nozaki and Shinji Hasegawa and Takashi Kawabe and Koji Kato and Seiji Kojima and Takaharu Matuyama and Tomoki Naoe",
year = "1998",
month = "5",
day = "1",
doi = "10.1097/00043426-199805000-00002",
language = "English",
volume = "20",
pages = "190--195",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Prognostic significance of TEL/AML1 fusion transcript in childhood B- precursor acute lymphoblastic leukemia

AU - Takahashi, Yoshiyuki

AU - Horibe, Keizo

AU - Kiyoi, Hitoshi

AU - Miyashita, Yoshiko

AU - Fukuda, Minoru

AU - Mori, Hiroshi

AU - Nozaki, Chika

AU - Hasegawa, Shinji

AU - Kawabe, Takashi

AU - Kato, Koji

AU - Kojima, Seiji

AU - Matuyama, Takaharu

AU - Naoe, Tomoki

PY - 1998/5/1

Y1 - 1998/5/1

N2 - Purpose: A retrospective study was conducted to investigate the prognostic significance of TEL/AML1 fusion resulting from a cryptic t(12;21) in Japanese patients with childhood B-precursor acute lymphoblastic leukemia (ALL). Materials and Methods: Leukemic samples from 144 children with newly diagnosed ALL (104 with CD10-positive B-precursor ALL, 11 with CD10-negative B-precursor ALL, 5 with BALL, and 24 with T-ALL) were analyzed by reverse- transcription polymerase chain reaction. Results: The frequency of patients with TEL/AML1 was 16% (23 of 144) and all patients with TEL/AML1 also had CD10-positive B-precursor ALL. TEL/AML1 was not found in any samples from the patients with T-ALL, B-ALL, or CD10-negative B-precursor ALL. Among patients with CD10-positive B-precursor ALL, age, initial white blood cell count, and immunophenotype did not differ with TEL/AML1 positivity, although the patients were predominantly male (p < 0.01). Clinical outcomes of 94 patients treated with recent protocols were analyzed. Five of the 21 (23.8%) patients with TEL/AML1 relapsed and 4 of these relapsed > 24 months after diagnosis. Although the overall 5-year survival rate was better among patients with TEL/AML1 fusion transcript than among those without it (87.3 ± 8.7% versus 75.9 ± 5.8%, respectively), the 5-year disease-free survival (DFS) rates of patients with TEL/AML1 fusion transcript and those without it were similar (64.0 ± 13.5% versus 69.1 ± 6.3%, respectively). However, for 57 patients treated with the latest intensive protocol, the 4-year DFS rate was much higher for the patients with TEL/AML1 fusion transcript than for those without it (100.0% v.s. 69.6 ± 8.4%, respectively, p = 0.1472). Conclusions: This study confirmed that TEL/AML1 gene fusion is the most common genetic event in pediatric ALL in Japan and is restricted to CD10-positive B- precursor ALL. Moreover, it was associated with an improved survival rate among patients treated with intensive therapy. Therefore, these data suggest that the patients with TEL/AML1 may not necessarily be candidates for less aggressive treatment.

AB - Purpose: A retrospective study was conducted to investigate the prognostic significance of TEL/AML1 fusion resulting from a cryptic t(12;21) in Japanese patients with childhood B-precursor acute lymphoblastic leukemia (ALL). Materials and Methods: Leukemic samples from 144 children with newly diagnosed ALL (104 with CD10-positive B-precursor ALL, 11 with CD10-negative B-precursor ALL, 5 with BALL, and 24 with T-ALL) were analyzed by reverse- transcription polymerase chain reaction. Results: The frequency of patients with TEL/AML1 was 16% (23 of 144) and all patients with TEL/AML1 also had CD10-positive B-precursor ALL. TEL/AML1 was not found in any samples from the patients with T-ALL, B-ALL, or CD10-negative B-precursor ALL. Among patients with CD10-positive B-precursor ALL, age, initial white blood cell count, and immunophenotype did not differ with TEL/AML1 positivity, although the patients were predominantly male (p < 0.01). Clinical outcomes of 94 patients treated with recent protocols were analyzed. Five of the 21 (23.8%) patients with TEL/AML1 relapsed and 4 of these relapsed > 24 months after diagnosis. Although the overall 5-year survival rate was better among patients with TEL/AML1 fusion transcript than among those without it (87.3 ± 8.7% versus 75.9 ± 5.8%, respectively), the 5-year disease-free survival (DFS) rates of patients with TEL/AML1 fusion transcript and those without it were similar (64.0 ± 13.5% versus 69.1 ± 6.3%, respectively). However, for 57 patients treated with the latest intensive protocol, the 4-year DFS rate was much higher for the patients with TEL/AML1 fusion transcript than for those without it (100.0% v.s. 69.6 ± 8.4%, respectively, p = 0.1472). Conclusions: This study confirmed that TEL/AML1 gene fusion is the most common genetic event in pediatric ALL in Japan and is restricted to CD10-positive B- precursor ALL. Moreover, it was associated with an improved survival rate among patients treated with intensive therapy. Therefore, these data suggest that the patients with TEL/AML1 may not necessarily be candidates for less aggressive treatment.

UR - http://www.scopus.com/inward/record.url?scp=0031867826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031867826&partnerID=8YFLogxK

U2 - 10.1097/00043426-199805000-00002

DO - 10.1097/00043426-199805000-00002

M3 - Article

C2 - 9628428

AN - SCOPUS:0031867826

VL - 20

SP - 190

EP - 195

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 3

ER -